Gilmore Neil O'Neill
Known title: CEOCIK: 0001742084
Associated companies
Transaction History
| EDIT | ▼ Sell | Open Market | 5,124 | $16K | 9/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 15,380 | $42K | 6/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 5,394 | $11K | 3/3/2026 | View on chart |
| EDIT | ▼ Sell | Open Market | 5,603 | $12K | 12/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 5,592 | $15K | 9/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 15,192 | $26K | 6/3/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 16,632 | $28K | 3/4/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 1,618 | $3K | 12/3/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 1,555 | $5K | 9/4/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 12,191 | $67K | 6/4/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 77,824 | $733K | 3/5/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 72,213 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 130,700 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 72,212 | $0 | 3/2/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 6,486 | $62K | 6/5/2023 | View on chart |
| EDIT | ▲ Buy | Grant | 50,000 | $0 | 3/2/2023 | View on chart |
| EDIT | ▲ Buy | Grant | 86,655 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.